Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Ming Bioventures

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 18
Average round size
The average size of a deal this fund participated in
Portfolio companies 17
Rounds per year 3.60
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Medical
  • Biopharma

Ming Bioventures appeared to be the VC, which was created in 2018. The main office of represented VC is situated in the Suzhou. The fund was located in Asia if to be more exact in China.

The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this Ming Bioventures performs on 4 percentage points more the average number of lead investments. The important activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Ming Bioventures, startups are often financed by Sequoia Capital China, SBCVC. The meaningful sponsors for the fund in investment in the same round are Yingqi Investment, Xiamen Changrong Investment Management, Tencent Holdings.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Medical Device, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight SyMap Medical, Viva Biotech.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Ming Bioventures:
Typical Co-investors
Ming Bioventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Ming Bioventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
6Rooms China, Shanghai
Alexandria Asset Management Arlington, United States, Virginia
Beishang Capital Beijing, Beijing, China
Blue Fund Herzliya, Israel, Tel Aviv
Chengdu Jieti Chuangtou Chengdu, China, Sichuan
dlab New York, New York, United States
Dongzhao Shanghai Group -
Dorcas Investments -
GRUPO BANCOLOMBIA Antioquia, Colombia, Medellín
i2i Ventures Islamabad, Pakistan
Inspovation Ventures California, Los Altos, United States
Maker Studios California, Culver City, United States
Prophetic Ventures India, Maharashtra, Mumbai
Stadtwerk Winterthur Switzerland, Winterthur, Zurich
Steven Gordon Family Foundation -
Telegraph Hill Capital California, San Francisco, United States
Trinity Health Livonia, Michigan, United States
UAE Exchange Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Whittvest Holdings -
Yanjiyou Chengdu, China, Sichuan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Shengyuan MicroPort

Health Care
Medical Device
$13M30 Dec 2022 Nanjing, Jiangsu, China

Mesai Biotech

Health Care
02 Sep 2022 Hangzhou, Zhejiang, China

Redbud Medicine

Health Care
$10M23 Aug 2022 Haidian, Beijing, China

Kossel Medical

Health Care
Medical Device
$15M01 Jan 2022 Suzhou, Jiangsu, China

Help Stem Cell Innovations

Health Care
Market Research
$25M15 Nov 2021 Xuanwu District, Jiangsu, China


$30M16 Sep 2021 -

Zion Pharma

$40M28 Jul 2021 Shanghai, China

Abogen Biosciences

Life Science
$92M08 Apr 2021 Gusu District, Jiangsu, China

Life Science
$20M22 Mar 2021 Lower Gwynedd Township, Pennsylvania, United States
Tavotek Biotherapeutics Snares $20M in Series A

– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ming Bioventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: